Infectious Agents Associated Cancers: Epidemiology and Molecular Biology by Qiliang Cai Zhenghong Yuan & Ke Lan

Author:Qiliang Cai, Zhenghong Yuan & Ke Lan
Language: eng
Format: epub
Publisher: Springer Singapore, Singapore

8.4 Effect of Anti-HCV Treatment on HCC Occurrence and Recurrence

8.4.1 Anti-HCV Treatment with Interferon (IFN)

Before the emergence of direct-acting antivirals before 2011, interferon (IFN)-based therapies are the standard treatment for HCV. The endpoint of treatment is a 6-month-long sustained virological response (SVR) after drug withdrawal. SVR is defined by undetectable HCV RNA below 10–15 international units [IU]/ml. Administration of a combination of pegylated IFN-α with ribavirin for 24 or 48 weeks yielded viral eradication in approximately 80% patients infected with HCV genotypes 2 and 3 or 40–50% of patients infected with HCV genotype 1 [109]. Probably due to the relative low efficacy of IFN therapy, a decreased incidence of HCC or lower recurrence of HCC in HCV-infected patients who receive IFN-based therapy is only observed in more than 5-year follow-up studies. Overall IFN-based therapies significantly benefit HCC patients after curative HCC therapy, which is probably due to the additional inhibitory effects of IFN on liver cancer rather than antiviral effect [21].

Download

Copyright Disclaimer:
This site does not store any files on its server. We only index and link to content provided by other sites. Please contact the content providers to delete copyright contents if any and email us, we'll remove relevant links or contents immediately.